BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29167891)

  • 1. The Promise and Challenges of CAR-T Gene Therapy.
    Kuehn BM
    JAMA; 2017 Dec; 318(22):2167-2169. PubMed ID: 29167891
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 4. CAR T-cell therapy in refractory large B-cell lymphoma.
    Stirrups R
    Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
    [No Abstract]   [Full Text] [Related]  

  • 5. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses After CAR-T Therapy.
    Abbasi J
    JAMA; 2018 Nov; 320(18):1850. PubMed ID: 30422179
    [No Abstract]   [Full Text] [Related]  

  • 7. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cell viability release testing and clinical outcomes: is there a lower limit?
    Chong EA; Levine BL; Grupp SA; Davis MM; Siegel DL; Maude SL; Gladney WL; Frey NV; Porter DL; Hwang WT; Chong ER; June CH; Schuster SJ
    Blood; 2019 Nov; 134(21):1873-1875. PubMed ID: 31554634
    [No Abstract]   [Full Text] [Related]  

  • 9. Tisagenlecleucel (Kymriah) for ALL.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):177-178. PubMed ID: 29039821
    [No Abstract]   [Full Text] [Related]  

  • 10. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
    Maude SL
    Clin Adv Hematol Oncol; 2018 Oct; 16(10):664-666. PubMed ID: 30543595
    [No Abstract]   [Full Text] [Related]  

  • 11. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.
    Zhang JP; Zhang R; Tsao ST; Liu YC; Chen X; Lu DP; Castillo P; Chang LJ
    Blood Adv; 2018 Jul; 2(14):1691-1695. PubMed ID: 30026294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
    Gill S; Porter DL
    Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
    Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
    Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Gauthier J
    Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
    Chung H; Jung H; Noh JY
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of surface CD3 expression in allogeneic CAR T-cells.
    Margolskee E; Pillai V
    Am J Hematol; 2020 Sep; 95(9):1115-1116. PubMed ID: 32129509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.